Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03526835
Other study ID # MCLA-158-CL01
Secondary ID 2017-004745-24
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date May 2, 2018
Est. completion date June 2025

Study information

Verified date March 2024
Source Merus N.V.
Contact Eduardo Pennella, MD
Phone +1 617 401 4499
Email USenquiries@merus.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the RP2D of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansion part of the study. Cohorts of selected solid tumor indications for which there is evidence of EGFR dependency and potential sensitivity to EGFR inhibition will be evaluated including head and neck cancer. The study will further assess the safety, tolerability, PK, PD, immunogenicity, and anti-tumor activity of MCLA-158.


Description:

Study Design: This open label, multicenter, first-in-human study consists of 2 parts. Part 1 is a dose escalation to find the recommended Phase II dose (RP2D) of MCLA-158 studying patients with metastatic colorectal cancer. Enrollment in the dose escalation part has been completed. Dose expansion (single-agent cohorts) In an expansion part of the study, the activity, safety, and tolerability of MCLA-158 at 1500 mg every 2 weeks (Q2W) (preliminary RP2D) as a single agent will be evaluated in cohorts of selected solid tumor indications with dependency on EGFR signaling. Eligible solid tumor indications may include locally advanced unresectable or metastatic HNSCC, gastric/gastroesophageal junction adenocarcinoma (GEA) with EGFR amplification and/or high EGFR expression, esophageal carcinoma and pancreatic adenocarcinoma. Additionally, safety will be characterized at two dose levels in this setting. Dose expansion (in combination with pembrolizumab cohort) MCLA-158 in combination with pembrolizumab will be explored first in HNSCC patients eligible to receive pembrolizumab as first-line monotherapy. Other expansion cohorts may be considered for combination treatment in the future.


Recruitment information / eligibility

Status Recruiting
Enrollment 360
Est. completion date June 2025
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically or cytologically confirmed solid tumors with evidence of metastatic or locally advanced disease not amenable to standard therapy with curative intent. - Expansion cohorts: patients with locally advanced unresectable or metastatic disease for the following indications: - COMBINATION FIRST-LINE HNSCC: patients eligible to receive pembrolizumab as first-line monotherapy with tumors expressing programmed cell death protein ligand 1 (PD-L1), combined positive score (CPS) =1, as determined by a Food and Drug Administration (FDA) approved test in the US, or by an approved equivalent test in other countries; patients should not have previous systemic therapy administered in the recurrent or metastatic setting, although previous systemic therapy as part of multimodal treatment for locally advanced disease is allowed if ended =6 months prior to signing the ICF. The eligible HNSCC primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx. Previous treatments with anti PD-(L)1 or anti-EGFR therapies are not allowed. - SINGLE AGENT SECOND-/THIRD-LINE HNSCC PATIENTS: patients who have progressed on or after, or are intolerant to, anti-PD-(L)1 therapy as monotherapy or in combination with other agents, and have progressed to a platinum-based chemotherapy less than 6 months from the last platinum dose, with no previous exposure to EGFR inhibitors. Patients with no more than 2 prior lines of treatment in recurrent or metastatic disease not amenable to standard therapy with curative intent. - Human papilloma virus (HPV) status determined by p16 immunohistochemistry (IHC) or molecular HPV test for all oropharyngeal tumors should be reported when available. - The eligible HNSCC primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx. - GEA with histologically confirmed EGFR amplification (fluorescence in situ hybridization [FISH] score EGFR/CEP7 ratio =2.0, or next generation sequencing [NGS] EGFR copy =8, or cfDNA =2.5, or EGFR IHC H-score =200) - Esophageal carcinoma - Pancreatic adenocarcinoma - Patients with other indications must have been previously treated with at least 2 lines of the standard approved therapy (when applicable) in the locally advanced/unresectable or metastatic setting. Patients with malignant salivary gland tumors and squamous esophageal cancer may be enrolled after progression on 1 line of systemic standard treatment. - A baseline fresh tumor sample (FFPE) from a metastatic or primary site. - Amenable for biopsy. - Measurable disease as defined by RECIST version 1.1 by radiologic methods. - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. - Life expectancy = 12 weeks, as per investigator. - Left ventricular ejection fraction (LVEF) = 50% by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA). - Adequate organ function Exclusion Criteria: - Central nervous system metastases that are untreated or symptomatic, or require radiation, surgery, or continued steroid therapy to control symptoms within 14 days of study entry. - Known leptomeningeal involvement. - Participation in another clinical trial or treatment with any investigational drug within 4 weeks prior to study entry. - Any systemic anticancer therapy within 4 weeks or 5 half-lives whichever is longer of the first dose of study treatment. For cytotoxic agents that have major delayed toxicity ( e.g. mitomycin C,nitrosoureas), or anticancer immunotherapies, a washout period of 6 weeks is required. - Requirement for immunosuppressive medication (e.g. methotrexate, cyclophosphamide) - Major surgery or radiotherapy within 3 weeks of the first dose of study treatment. Patients who received prior radiotherapy to =25% of bone marrow are not eligible, irrespective of when it was received. - Persistent grade >1 clinically significant toxicities related to prior antineoplastic therapies (except for alopecia); stable sensory neuropathy = grade 2 NCI-CTCAE v4.03 is allowed. - History of hypersensitivity reaction or any toxicity attributed to human proteins or any of the excipients that warranted permanent cessation of these agents. - Uncontrolled hypertension (systolic > 150 mmHg and/or diastolic > 100 mmHg) with appropriate treatment or unstable angina. - History of congestive heart failure of Class II-IV New York Heart Association (NYHA) criteria, or serious cardiac arrhythmia requiring treatment (except atrial fibrillation, paroxysmal supraventricular tachycardia). - History of myocardial infarction within 6 months of study entry. - History of prior malignancies with the exception of excised cervical intraepithelial neoplasia or nonmelanoma skin cancer, or curatively treated cancer deemed at low risk for recurrence with no evidence of disease for at least 3 years. - Current dyspnea at rest of any origin, or other diseases requiring continuous oxygen therapy. - Patients with a history of interstitial lung disease (e.g.: pneumonitis or pulmonary fibrosis) or evidence of ILD on baseline chest CT scan. - Current serious illness or medical conditions including, but not limited to uncontrolled active infection,clinically significant pulmonary, metabolic or psychiatric disorders. - Patients with the following infectious diseases: - Active hepatitis B infection (HBsAg positive) without receiving antiviral treatment. Note: Patients with active hepatitis B (HBsAg positive) must receive antiviral treatment with lamivudine, tenofovir, entecavir, or other antiviral agents, starting at least =7 days before the initiation of the study treatment. Patients with antecedents of hepatitis B (anti-HBc positive, HBsAg and HBV-DNA negative) are eligible. - Positive test for hepatitis C ribonucleic acid (HCV RNA). Note: Patients in whom HCV infection resolved spontaneously (positive HCV antibodies without detectable HCV-RNA) or who achieved a sustained response after antiviral treatment and show absence of detectable HCV RNA =6 months (with the use of IFN-free regimens) or = 12 months (with t the use of IFN-based regimens) after cessation of antiviral treatment are eligible. - Patients with current cirrhotic status of Child-Pugh class B or C; known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC. - Pregnant or lactating women; patients of childbearing potential must use highly effective contraception methods prior to study entry, for the duration of study participation, and for 6 months after the last dose of MCLA-158.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
MCLA-158
full-length IgG1 bispecific antibody targeting EGFR and LGR5
Combination Product:
MCLA-158 +Pembrolizumab
MCLA-158 in combination with pembrolizumab (non-IMP) will be explored first in HNSCC patients eligible to receive pembrolizumab as first-line monotherapy.

Locations

Country Name City State
Belgium Cliniques universitaires Saint-Luc Brussels
Belgium Institut Jules Bordet Brussels
Belgium UZ Gent Gent
Belgium Chu Ucl Namur Site De Sainte-Elisabeth Namur
France Hopital Saint Andre, CHU Bordeaux Bordeaux
France Centre Leon Berard Lyon
France Hopital La Timone Marseille
France Institut Régional du Cancer de Montpellier Montpellier
France Centre Antoine Lacassagne Nice
France Institut Curie Paris
France Institut Gustave Roussy Paris
France Centre Henri Becquerel Rouen
Netherlands NKI - Antoni van Leeuwenhoek Amsterdam
Netherlands UMC Radboud Nijmegen
Netherlands UMC Utrecht Utrecht
Spain Vall d'Hebron Barcelona
Spain Hospital 12 de Octubre Madrid
Spain Clinica Universidad de Navarra Pamplona
Spain Complejo Hospitalario de Navarra Pamplona
Spain Instituto Valenciano de Oncologia Valencia
United Kingdom Cambridge University Hospitals NHS Foundation Trust Cambridge
United Kingdom Sarah Cannon Research Institute London
United States Cleveland Clinic Cleveland Ohio
United States Texas Oncology Dallas Texas
United States Florida Cancer Specialists Fort Myers Florida
United States Oncology Consultants Houston Texas
United States UCSD La Jolla California
United States Rocky Mountain Cancer Centers Lone Tree Colorado
United States USC Norris Comprehensive Cancer Center Los Angeles California
United States The University Of Tennessee Health Science Center Memphis Tennessee
United States Sarah Cannon Research Institute Nashville Tennessee
United States SSM OKC Hightower Clinical Oklahoma City Oklahoma
United States Sarah Cannon Research Institute (Lake Nona) Orlando Florida
United States Oncology & Hematology Associates of Southwest Virginia Roanoke Virginia
United States SSM Health Saint Louis University Hospital Saint Louis Missouri
United States University of Utah Health Huntsman Cancer Hospital Salt Lake City Utah
United States Utah Cancer Specialists Salt Lake City Utah
United States Cancer Care Northwest Spokane Washington
United States Texas Oncology Tyler Texas

Sponsors (1)

Lead Sponsor Collaborator
Merus N.V.

Countries where clinical trial is conducted

United States,  Belgium,  France,  Netherlands,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Escalation & Expansion: Biomarkers for Wnt signaling proteins Evaluation of biomarker results for Wnt signaling proteins 36 months
Other Escalation & Expansion: Biomarkers for genetic aberrations in ctDNA Evaluation of biomarker results in genetic aberrations in ctDNA 36 months
Other Escalation & Expansion: Biomarkers for differential expression of miRNA Evaluation of biomarker results for differential expression of miRNA 36 months
Other Escalation & Expansion: Biomarkers for differential expression of mRNA Evaluation of biomarker results for differential expression of mRNA 36 months
Primary Escalation: Number of patients with Dose Limiting Toxicities (DLTs) Evaluation of number of participants with treatment related toxicities observed during the dose escalation. 6-12 months
Primary Escalation: Severity of Dose Limiting Toxicities (DLT) Evaluation of the severity of treatment related toxicities observed during the dose escalation. 6-12 months
Primary Escalation and Expansion: Safety and tolerability: laboratory values Number of participants with abnormal laboratory tests results 6-12 months
Primary Dose Expansion (Combination): Safety and tolerability: AEs and SAEs Incidence, severity, and relationship of AEs and SAEs, in combination with pembrolizumab in HNSCC 6-12 months
Primary Escalation and Expansion: Safety and tolerability: (ECG) Number of participants with abnormal ECG readings 6-12 months
Primary Escalation and Expansion: Safety and tolerability: vital signs Number of participants with abnormal vital signs 6-12 months
Primary Escalation and Expansion: Safety and tolerability Treatment discontinuations due to AEs and dose modifications due to AEs 6-12 months
Primary Expansion (single agent - non-randomized): Objective overall response rate (ORR) Evaluation of clinical benefit assessed by RECIST v1.1 determining objective overall response rate (ORR) 36 months
Primary Escalation: RP2D To determine the preliminary RP2D of single agent petosemtamab in mCRC patients who have progressed on chemotherapy, with or without an anti-vascular endothelial growth factor (VEGF) therapy, and with an anti-EGFR therapy (if RASwt) 36 months
Primary Expansion (single agent, randomized expansion in 2/3L Head and Neck cancer- Incidence and severity and relationship of AEs and SAEs To descriptively characterize all relevant clinical safety and efficacy data within the study 12 months
Primary Expansion (single agent, randomized expansion in 2/3L Head and Neck cancer- Treatment discontinuations due to AEs and dose modifications due to AEs To descriptively characterize all relevant clinical safety and efficacy data within the study 12 months
Primary Expansion (single agent, randomized expansion in 2/3L Head and Neck cancer- Best overall response To descriptively characterize all relevant clinical safety and efficacy data within the study 12 months
Primary Expansion (single agent, randomized expansion in 2/3L Head and Neck cancer- Incidence of AEs and SAEs To characterize the exposure-safety relationship of petosemtamab administered at 1100 mg and 1500 mg Q2W in terms of TEAEs 12 months
Primary Expansion (single agent, randomized expansion in 2/3L Head and Neck cancer- Incidence of TEAEs To characterize the incidence of TEAEs at Week 8 8 weeks
Secondary Escalation & Expansion: Incidence of anti-drug antibodies against MCLA-158 Number of participants with anti-drug antibodies against MCLA-158 36 months
Secondary Escalation & Expansion: Serum titers of anti-drug antibodies Serum titers of anti-drug antibodies against MCLA-158 36 months
Secondary Escalation & Expansion (non-randomized cohort): Cytokine Panel Expression Profile Evaluation of the cytokine expression profile 36 months
Secondary Escalation & Expansion: Biomarkers for EGFR activation and signaling Evaluation of biomarker results for EGFR activation and signaling 36 months
Secondary Escalation & Expansion: EGFR expression Biomarkers in tumor samples relevant to EGFR expression in relation to early tumor response profile of MCLA-158 36 months
Secondary Escalation & Expansion: LGR5 expression Biomarkers in tumor samples relevant to LGR5 expression in relation to early tumor response profile of MCLA-158 36 months
Secondary Escalation & Expansion: Duration of response (DOR) Evaluation of clinical benefit assessed by RECIST v1.1 determining duration of response (DOR) 36 months
Secondary Escalation & Expansion: Progression Free Survival (PFS) and survival Evaluation of clinical benefit assessed by RECIST v1.1 determining objective progression free survival (PFS) and/or survival 36 months
Secondary Escalation & Expansion: End of infusion (EOI) plasma concentration [Ceoi] End of infusion (EOI) plasma concentration [Ceoi] as measured from all individual plasma concentrations 36 months
Secondary Escalation & Expansion: Maximum plasma concentration [Cmax] Maximum plasma concentration as measured from all individual plasma concentrations 36 months
Secondary Escalation & Expansion: Plasma concentration at 0 hours [C0h] Plasma concentration at 0 hours [C0h] as measured from all individual plasma concentrations 36 months
Secondary Escalation & Expansion: Area under the concentration versus time curve from time zero to time t [AUC0-t] Area under the concentration versus time curve from time zero to time t [AUC0-t] 36 months
Secondary Escalation & Expansion: Area under the concentration versus time curve [AUC0-8] Area under the concentration versus time curve [AUC0-8] 36 months
Secondary Escalation & Expansion: Clearance of plasma [CL] Clearance of plasma [CL] 36 months
Secondary Escalation & Expansion: Volume of distribution at steady state [Vss] Volume of distribution at steady state [Vss] 36 months
Secondary Escalation & Expansion: Time to reach maximum concentration [tmax] Time to reach maximum concentration [tmax] 36 months
Secondary Escalation & Expansion: Half-life [t1/2] Half-life [t1/2] 36 months
Secondary Expansion: Frequency of Treatment-Related Adverse Events (AE) Evaluation of the number of participants with AEs or SAEs that are related to treatment as assessed by CTCAE version 4.03 up to 30 days post-last dose
Secondary Expansion: Severity of Treatment-Related Adverse Events (AE) Evaluation of the severity of AEs that are related to treatment as assessed by CTCAE version 4.03 up to 30 days post-last dose
Secondary Expansion: Frequency of dose interruptions and reductions Evaluation of the number of dose interruptions and reductions up to 30 days post-last dose
Secondary Escalation & Expansion: Overall survival (OS) Evaluation of clinical benefit assessed by RECIST v1.1 determining overall survival (OS) 36 months
Secondary Expansion (single agent, randomized expansion in 2/3L Head and Neck cancer): exposure-efficacy relationship of petosemtamab administered at 1100 mg and 1500 mg: Target Lesions Percentage change from baseline in sum of the diameters of target lesions at Week 8 8 weeks
Secondary Expansion (single agent, randomized expansion in 2/3L Head and Neck cancer): exposure-efficacy relationship of petosemtamab administered at 1100 mg and 1500 mg: TEAEs Incidence of Grade 3-4 TEAEs at Week 8 8 weeks
Secondary Expansion (single agent, randomized expansion in 2/3L Head and Neck cancer): exposure-efficacy relationship of petosemtamab administered at 1100 mg and 1500 mg: IRR TEAEs Incidence of IRR TEAEs at Week 8 8 weeks
Secondary Expansion (single agent, randomized expansion in 2/3L Head and Neck cancer): exposure-efficacy relationship of petosemtamab administered at 1100 mg and 1500 mg : non-IRR TEAEs Incidence of non-IRR TEAEs at Week 8 8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A